DBV Technologies S.A. (DBVT) stock
DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF
$10.27−0.75 (-6.81%)
Close on Nov 16, 2026Market cap $645.76MP/E –Yield –
DBV Technologies operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
DBV Technologies's operating income for the twelve months ending Sep 30, 2026 was -$208.36M. For fiscal 2025 it was -$147.06M. The highest annual figure on record is -$76.43M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$147.06M | – |
| FY2024 | Dec 31, 2024 | -$116.59M | – |
| FY2023 | Dec 31, 2023 | -$76.43M | – |
| FY2022 | Dec 31, 2022 | -$96.63M | – |
| FY2021 | Dec 31, 2021 | -$98.61M | – |
| FY2020 | Dec 31, 2020 | -$158.84M | – |
| FY2019 | Dec 31, 2019 | -$171.02M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$64.80M | – |
| Q2 FY2026 | Jun 30, 2026 | -$50.60M | – |
| Q1 FY2026 | Mar 31, 2026 | -$47.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$45.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$34.30M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.10M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.86M | – |
| Q3 FY2024 | Sep 30, 2024 | -$30.33M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$28.56M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.92M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.08M | – |
| Q1 FY2023 | Mar 31, 2023 | -$21.17M | – |
| Q4 FY2022 | Dec 31, 2022 | -$38.02M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.77M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$31.13M | – |
| Q1 FY2021 | Mar 31, 2021 | -$29.63M | – |
| Q4 FY2020 | Dec 31, 2020 | -$40.16M | – |
| Q3 FY2020 | Sep 30, 2020 | -$29.77M | – |
| Q2 FY2020 | Jun 30, 2020 | -$47.69M | – |
| Q1 FY2020 | Mar 31, 2020 | -$41.22M | – |
See a number that looks wrong?